|Bid||84.15 x 3100|
|Ask||84.16 x 800|
|Day's Range||84.02 - 84.24|
|52 Week Range||16.69 - 84.48|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.55|
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund (XBI) climbed 22.8% through Thursday, and the iShares Nasdaq Biotechnology Index (IBB) advanced 19.8%, compared with a 6.4% gain for the S&P 500 (SPX) The seven stocks I singled out in that column have done well: They jumped 26.6%. “Washington is very focused on impeachment and trade talks,” says Jefferies biotech analyst Michael Yee.
WILMINGTON, Del., Dec. 10, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Audentes Therapeutics, Inc. (NASDAQ GS: BOLD) regarding possible breaches of.
BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of The Medicines Company ("TMC" or "the Company") (MDCO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Novartis AG. Under the terms of the agreement, TMC shareholders will receive only $85.00 for each share of TMC common stock owned. The investigation concerns whether the TMC Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Novartis is underpaying for the Company.
NEW YORK, Dec. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ: MDCO)The.
NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
NEW YORK, NY / ACCESSWIRE / DECEMBER 5, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
The volume of global M&A has already reached $3.6 trillion this year, according to data from Dealogic. As history has shown, it takes just one big signature Merger Monday to symbolize hubris and excess—and it may already have happened.
NEW YORK, Dec. 04, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: TD Ameritrade Holding Corporation (NASDAQ:.
WILMINGTON, Del., Dec. 03, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: The Medicines Company (NASDAQ GS: MDCO) regarding possible breaches of.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating The Medicines Company (the "Company") (Nasdaq: MDCO) relating to the sale of the Company to Novartis AG. Under the terms of the transaction, shareholders of the Company will receive $85.00 in cash for each share of the Company common stock owned.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
NEW YORK, NY / ACCESSWIRE / December 2, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
(Bloomberg Opinion) -- Drugmakers have spent years de-emphasizing heart medications in favor of higher-priced treatments for cancer and rare diseases. As America enters its most caloric season, it looks like that is starting to change, for now. Novartis AG made a particularly large commitment Sunday with its $9.7 billion purchase of Medicines Co. and its promising new cholesterol drug. Meanwhile, biotechnology company Amarin Corp.’s bet on its fish-oil-derived capsule Vascepa is starting to pay off: Its shares soared earlier this month after a Food and Drug Administration panel recently suggested the pill — which was shown to cut cardiac risk in a huge trial last year — be made available to millions of additional patients. Heart medicines are also key pipeline components or sales drivers at a number of big pharmaceutical companies as well, from Merck & Co. and Bayer AG to Pfizer Inc.Investment in cardiac medicines is positive for patients and public health; after all, heart disease remains the most significant cause of death in the U.S. There’s a reason that drugmakers had backed away, however. These companies will have to navigate a harsh market environment to keep this mini-renaissance alive. Effective heart disease medicines, including statins for cholesterol and drugs for high blood pressure, have become much cheaper as generic options have hit the market. That’s excellent for patients and health budgets, as expanded use of these drugs has been impactful enough to slow Medicare spending growth. But it makes things difficult for newer, higher-priced medicines to make inroads. Next-generation drugs need to prove they can add something on top of or substantially outperform cheaper options to have a chance at anything but niche success. They sometimes still struggle even if they do. Cardiovascular drugs take time to have an impact, and the American health-care system isn’t patient. People change health insurance all the time as they swap or lose jobs, pick a new plan, or have one selected for them. Health plans often focus on annual costs and don’t always want to pay extra for an uncertain benefit that might eventually save someone else money. That tendency is most pronounced in large markets, where rapid uptake of a new drug translates into substantial spending increases.Two relatively new cholesterol drugs — Praluent, from Sanofi and Regeneron Pharmaceutical Co., and Amgen Inc.’s Repatha — are the most significant recent cautionary tales. They were both approved in 2015 with high expectations and are effective medications, but the market balked at their high price and threw up barriers to access. The result was a glacial launch. Sales remain sluggish even after major price cuts. Medicine Co.’s inclisiran lowers cholesterol at a similar rate by using the same drug target as those medicines but requires far less frequent dosing. Novartis will have to find out whether convenience is enough to command a premium price and avoid the same commercial fate. As for Amarin, a drug-price watchdog called Vascepa a rare cost-effective option for heart disease earlier this year. That doesn’t guarantee a rapid ascent to blockbuster sales. The drug’s future is partially in the FDA’s hands. The exact language of the agency’s expanded approval will help determine how many new patients will get access. The bigger part is arguably once again up to health plans. They will decide how strictly to interpret the FDA’s guidelines, and whether patients will have to jump through hoops to get the medicine. The size of the potential patient population may inspire them to clamp down, cost-effectiveness be damned. The barriers to heart drugs are navigable. Novartis was likely inspired to pay up for Medicines because it managed the feat with its heart-failure treatment Entresto. Sales of the drug started extremely slowly, but are now growing at a respectable clip. There is a clear opportunity in this somewhat neglected space. Profiting from it might require a high risk tolerance and an extra measure of patience. To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
The home of the Fighting Irish had a large position in the drug company at the end of the third quarter, and it’s nearly doubled in value since. It also sold Netflix stock, and bought Morgan Stanley and Alibaba stock.
Arrowhead Pharmaceuticals grabbed an upgrade Friday as ARWR stock has rocketed 159% since October on enthusiasm for the biotech company's RNAi platform. ARWR stock is 98% above a buy point.
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
NEW YORK, NY / ACCESSWIRE / November 27, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Tiffany & Co. (NYSE:TIF) The investigation concerns ...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of The Medicines Co. ("MDCO" or the "Company") (NASDAQ: MDCO) in connection with the proposed acquisition of the Company by Swiss pharmaceutical company Novartis International A.G. Under the terms of the acquisition agreement, MDCO shareholders will receive $85.00 for each share they own.